FDA Updates Label for Controversial Alzheimer ' s Drug Aduhelm FDA Updates Label for Controversial Alzheimer ' s Drug Aduhelm

The new label emphasizes that the drug should only be initiated in patients with mild cognitive impairment as a result of Alzheimer ' s disease or mild dementia stage of disease.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Psychiatry News Source Type: news